Image default
Synthetic Biology Technology

Exclusive expert insights from day one of SynBio Markets 2019.

Opening Keynote Panel (L-R)  – Ginkgo Bioworks Airbus, Intrexon, Inscripta, Purple Orange Ventures, AMSilk, Leaps by Bayer and Science Matters. (c) Liz Gyekye

Germany’s capital has seen a buzz of activity in recent weeks due to daylong celebrations commemorating 30 years since the fall of the Berlin Wall – an era that ushered in the end of communism and national reunification. Another era has started today with the launch of Bio Market Insight’s first SynBio Markets conference, which has kicked off with a bang. Set in the quirky ewerk location in Berlin, Germany, industry heavyweights have taken part in keynotes,  panel debates, sessions and roundtables to discuss the key issues affecting the synthetic biology industry.

Overall, Day One of the conference has seen dynamic content, a host of networking opportunities and bespoke partnering platforms. Essentially, it has equipped the synbio community with the knowledge and connections it needs to succeed.

Key themes that have emerged have been the importance of the team in growing a synbio business, huge opportunities around veganism, bridging the gap between academia and entrepreneurship, challenges around communications (there’s little love for the term synthetic biology) and the danger that the moment of scale up can bring.

The Bio Market Insight’s team has been hard at work reporting on the proceedings. Check our Twitter account @Bio_Markets and the hashtag #SynBioMarkets19 for photos, quotes and news. But we’ve also picked out some of the key insights from the first day, we’ll publish highlights of the second day same time tomorrow!

“We capture 50% of all the funding that goes into genomics research in Canada” – Bettina Hamelin, President and CEO at Ontario Genomics.

“We need to deliver tangible products that offer benefits to people” –  Randal Kirk, CEO of Intrexon.

“One of the key aspects of my job is to manage expectations” – Detlev Konigorski,  Innovation Manager for Emerging Technologies and Concepts at Airbus.

“Novo Holdings is an active life science investor” – Thomas Grotkjær, Principal, Novo Seeds.

“We need to fuel innovation and help the next generation of innovators” – Jason T Gammack, COO at Inscripta.

“We need companies like Ginkgo to help us to advance”, Jens Klein, CEO at AMSilk.

“It’s up to us to decide where we want to go. Do we want to save the planet or do we wreck it?” – John Collins, Operations and Commercial Director at SynbiCITE

“New tools offer exciting advances for engineering biology” – Jussi Jantti, Principal Scientist at VTT.

“The world needs biological answers” – Gernot J.Abel, Science Manager at  Novozymes
“The future we will inhabit is guaranteed to be different, but the shape it will take is yet to be determined.” – Christopher Preston, author and professor of Philosophy, Fellow at Program on Ethics and Public Affairs, University of Montana. 

If you were interested in reading this SynBio Markets ’19 story, you may also be interested in the synbio stories below.

Speaker Interview: 5 Minutes with…Alexander Murer from Kilobaser.

Speaker Interview:  5 Minutes With…Gernot Abel from Novozymes.

Speaker Interview: 5 Minutes With…Seiji Hirasaki from OriCiro Genomics.

Download: Bringing synthetic biology innovations to commercial scale report.

Speaker Interview: 5 Minutes With…Kate Krueger from New Harvest.

Speaker Interview: 5 Minutes With…John Husnik from Renaissance BioScience.

Related posts

‘Terrifying limbless chickens,’ form part of Boris Johnson’s bizarre view of synthetic biology.

Luke Upton

New biocomposite made from 90 percent renewable feedstock delivers on strength and durability.

Emily Odowd

VTT develops new bio-based plastic from cellulose and fatty acids

Liz Gyekye

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More